Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]
Discontinued
Reference number: GID-TA10413
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab in combination for untreated extensive-stage small-cell lung cancer.
Please note that following on from advice received from the company the timelines for this appraisal will be confirmed.
As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.